Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

J. Remon, L. E. Hendriks, C. Cabrera, N. Reguart, B. Besse*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

30 Citations (Web of Science)
131 Downloads (Pure)

Abstract

Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC) in first- and second-line setting improving the prognosis of these patients. However, the treatment landscape has been also drastically overturned with the advent of targeted therapies in oncogenic-addicted advanced NSCLC patients. Despite ICIs represent an active and new treatment option for a wide range of advanced NSCLC patients, the efficacy and the optimal place of ICI in the treatment strategy algorithm of oncogenic-addicted tumors remains still controversial, as only a minority of trials with ICI enrol oncogenic-addicted NSCLC patients previously treated with standard therapy. Therefore, there are still several open questions about ICI in oncogenic-driven NSCLC, such as the efficacy and toxicities, which need to be addressed before considering treatment with ICI as a standard approach in this population. It is in this framework, we provide a thorough overview on this currently controversial topic.

Original languageEnglish
Pages (from-to)47-58
Number of pages12
JournalCancer Treatment Reviews
Volume71
DOIs
Publication statusPublished - Dec 2018

Keywords

  • Immunotherapy
  • EGFR
  • ALK
  • ROS1
  • BRAF
  • Advanced non-small cell lung cancer
  • IMMUNE CHECKPOINT INHIBITORS
  • DABRAFENIB PLUS TRAMETINIB
  • LIGAND 1 EXPRESSION
  • OPEN-LABEL
  • PD-L1 EXPRESSION
  • MOLECULAR CHARACTERISTICS
  • 1ST-LINE TREATMENT
  • ANTITUMOR-ACTIVITY
  • HER2 MUTATION
  • STAGE IV

Cite this